Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Treasury union on FDA lab closures

This article was originally published in The Tan Sheet

Executive Summary

The National Treasury Employees Union announces Feb. 12 it sent a letter to Rep. John Dingell, D-Mich., and Rep. Bart Stupak, D-Mich., to halt proposed FDA Office of Regulatory Affairs lab closures. NTEU President Colleen M. Kelley says in a release the lab closures would compromise food safety. Kelley also says she disapproves of FDA's lack of communication with its employees, "I find it particularly egregious that the agency would let corrosive rumors about closings and consolidations spread throughout the workplace." NTEU's letter follows on the heels of a letter 20 senators sent to FDA Commissioner Andrew C. von Eschenbach in January, saying the lab closures should undergo a congressional review (1"The Tan Sheet," Feb. 5, 2007, p. 13)...

You may also be interested in...



Senators Ask ORA To Halt Lab Closure Pending Congressional Review

The Office of Regulatory Affairs' plan to close FDA labs should "undergo congressional review" according to a letter 20 senators sent to Commissioner Andrew von Eschenbach Jan. 30

EMA's Decision On Ranitidine Remaining Available Could Come At End Of April

Following the US request for ranitidine drugs to be withdrawn from the market, the European Medicines Agency says it would decide the fate of the products in the EU after wrapping up its own inquiry.

Perrigo Has Approval For Copy Of OTC Voltaren Arthritis Relief Before GSK Launches The Brand

Perrigo will launch generics of GSK's OTC Voltaren Arthritis Pain drug later in 2020 following FDA approval of its ANDA. GSK, which received FDA's OTC switch approval in February, still hasn't launched the product or indicated when it will.

Topics

UsernamePublicRestriction

Register

PS100240

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel